← FDA DRUG APPROVALS

FDA ANDA · ANDA062833

BACITRACIN ZINC-NEOMYCIN SULFATE-POLYMYXIN B SULFATE

Sponsor: NASKA

APPLICATION
ANDA062833
TYPE
ANDA
ROUTE
TOPICAL
DOSAGE FORM
OINTMENT
MARKETING STATUS
Discontinued

Products

BACITRACIN ZINC-NEOMYCIN SULFATE-POLYMYXIN B SULFATEDiscontinued
BACITRACIN ZINC 400 UNITS/GM, NEOMYCIN SULFATE EQ 3.5MG BASE/GM, POLYMYXIN B SULFATE 5,000 UNITS/GM · OINTMENT · TOPICAL
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industry →GMP discipline →FDA drug shortages →FDA enforcement & recalls →

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →